Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH)

Authors

Institutions

Publication Details

Journal
Future Cardiology
Published
2025-06-17
DOI
https://doi.org/10.1080/14796678.2025.2507466
Citations
1
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH)

Brittany N. Davis, James White, Natalie Patzlaff, Tara Suplicki
1 citations
Future Cardiology
Pulmonary Hypertension Research and Treatments
1.52
article

Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH)

Brittany N. Davis, James White, Natalie Patzlaff, Tara Suplicki
article en
1 citations

Abstract

No abstract available for this paper.
Future CardiologyVol. 21(9)
Pulmonary Hypertension Association (US), University of Rochester Medical Center (US), Triangle (US), United Therapeutics (United States) (US), G1 Therapeutics (United States) (US)
Openalex Percentile: Top 17%
Pulmonary Hypertension Research and Treatments
1.52
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH) — Brittany N. Davis, James White, et al. · Future Cardiology (2025) | TGRS Research Map | TGRS